MPL and autoimmune thrombocytopenic purpura: The paucity of literature on the use of innovating effective agents in ITP and HUS (as thrombopoietin-receptor agonists or eculizumab), implies difficult decisions concerning risks of fetal and maternal outcomes associated with disease progression, against safety issues of their usage during pregnancy.